Dr Moya Clancy

  • Lecturer in Clinical Psychology (Mental Health & Wellbeing)

email: Moya.Clancy@glasgow.ac.uk

Clarice Pears Building, 90 Byres Rd, Glasgow, G12 8TB

Import to contacts

Biography

Moya is a qualified Clinical Psychologist and Trial Coordinator for the AVATAR2 Trial (Home | AVATAR2 Therapy Trial | Mental Health Research (avatartherapytrial.com)

Moya began her journey in Cork, Ireland, where she graduated with a BA(Hons) in Applied Psychology from University College Cork (UCC). Moya then completed her MSc in Clinical Mental Health Sciences at University College London (UCL), where she completed research exploring the roles of trauma and dissociation in information processing and subsequent intrusive memories among psychosis-prone individuals. During this time, Moya also worked as a Support Worker and Honorary Assistant Psychologist with an Early Intervention for Psychosis Team in Central & North West London, NHS. Following this, Moya worked in a variety of Assistant Psychologist roles including with the Irish Prison Service, Older Adult Service (HSE) and Child and Adolescent Mental Health Service (HSE).  

Moya completed her Doctorate in Clinical Psychology at the University of Glasgow, where she specialised in the areas of trauma and psychosis (thesis title: From trauma to psychosis: developing an interventionist-causal approach for dissociation and voice-hearing in people with complex trauma). Moya was fortunate to complete a joint specialist placement with the Glasgow Psychological Trauma Service and Esteem Early Intervention for Psychosis Service.  

Moya is currently working as the Trial Coordinator for the AVATAR2 Trial in Glasgow and as an Honorary Clinical Psychologist with Esteem Early Intervention for Psychosis Service.  

In her downtime, Moya is an avid gig-goer and lover of all things music, likes cooking and getting outdoors to explore the wondrously beautiful Scotland.  

Publications

List by: Type | Date

Supervision

Moya provides supervision to Research Assistants of the AVATAR2 trial.